Solventum CORP 8-K filings

Solventum announced robust second-quarter 2026 financial results, including a 9.5% organic sales increase and a 50.9% rise in adjusted diluted EPS, while also revealing plans to separate its Health Information Systems business.

Solventum Corporation announced its intention to separate its Health Information Systems business as part of a portfolio optimization strategy, aiming to unlock shareholder value and focus on its MedTech offerings.

Solventum Corporation announced the appointment of Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026.

Solventum Corporation has reached a settlement to resolve a shareholder class action lawsuit regarding its by-laws.

Solventum Corporation has adopted a new Executive Severance Plan, effective June 1, 2026, modifying severance benefits for eligible employees and executive officers.

Solventum Corporation announced the results of its annual shareholder meeting held on May 15, 2026, with all proposals passing.

Solventum reported first-quarter 2026 financial results, with sales down 3.0% reported but up 2.1% organically, and affirmed full-year guidance.

Solventum Corporation's Chief Accounting Officer, Mary Wilcox, has announced her intent to retire and resign following the appointment of her successor.

Solventum reported solid fourth-quarter 2025 financial results, surpassing full-year sales and EPS expectations, and introduced its 2026 full-year guidance.

Solventum Corporation reflects on a successful first year as a standalone public company, highlighting strategic execution, financial outperformance, and key growth initiatives.

Solventum reported solid third-quarter 2025 financial results with increased organic sales, a raised full-year adjusted EPS outlook, and launched a new multiyear 'Transform for the Future' initiative.

Solventum Corporation announced the appointment of Heather Knight as its new Chief Commercial Officer, effective November 10, 2025, alongside the departure of Chris Barry.

Solventum announced the early tender results and pricing of its upsized cash tender offers for outstanding debt securities, increasing the aggregate purchase price to $2.0 billion.

Solventum announced the completion of its Purification & Filtration business sale to Thermo Fisher Scientific for $4.0 billion, boosting its balance sheet and updating 2025 guidance.

Solventum Corporation announced cash tender offers to repurchase up to $1.75 billion of its outstanding senior notes across two pools.

3M Company has completed a secondary offering of 8.8 million Solventum common shares, generating approximately $648 million, with Solventum receiving no proceeds.

Solventum Corporation amended its agreement to sell its purification and filtration business to Thermo Fisher Scientific, reducing the cash consideration to $4.0 billion and excluding its drinking water filtration business.

Solventum reported solid second-quarter 2025 financial results, marked by positive sales volume growth and an increased full-year guidance for organic sales and adjusted earnings per share.

Solventum Corporation announced an amended agreement with Thermo Fisher Scientific Inc. to sell its purification and filtration business for approximately $4.00 billion, excluding its drinking water filtration business, which is expected to increase EPS accretion while reducing projected margin improvements.

Solventum's first quarter 2025 results show a 2.6% increase in reported sales and a 4.3% increase in organic sales, leading to an increased full-year organic sales growth outlook.

Solventum Corporation held its annual shareholder meeting on April 30, 2025, and announced the voting results for the election of directors, executive compensation, and the ratification of the company's independent auditor.

Solventum Corporation has entered into a definitive agreement to sell its purification and filtration business to Thermo Fisher Scientific for approximately $4.1 billion in cash, subject to customary adjustments.

Solventum reports a 1.9% increase in reported sales for Q4 2024, alongside the introduction of full-year 2025 guidance.

Solventum reported a 0.4% increase in sales and raised its full-year guidance for organic sales growth, adjusted EPS, and free cash flow after exceeding expectations for the second consecutive quarter.

Solventum Corporation has adopted a new Executive Change in Control Severance Plan to provide enhanced benefits to executives in the event of involuntary termination related to a change in control.

Solventum Corporation's Board of Directors approved amendments to the company's bylaws, updating procedures for stockholder meetings and director nominations.

Solventum's second-quarter results show a slight increase in sales and improved earnings per share, leading to an upward revision of the company's full-year financial outlook.

Solventum Corporation's Talent Committee approved new forms of restricted stock unit and performance share unit agreements, granting awards to key executives and directors.

Solventum, a newly independent company, reported its first quarter 2024 financial results, showing a slight increase in sales and reaffirming its full-year guidance.

Solventum Corporation has appointed Shirley A. Edwards, a former EY partner, to its Board of Directors, effective April 12, 2024.